Trevi Therapeutics, Inc. (TRVI)
Automate Your Wheel Strategy on TRVI
With Tiblio's Option Bot, you can configure your own wheel strategy including TRVI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TRVI
- Rev/Share 0.0
- Book/Share 0.8456
- PB 6.7168
- Debt/Equity 0.0096
- CurrentRatio 15.3832
- ROIC -0.5084
- MktCap 676743600.0
- FreeCF/Share -0.3512
- PFCF -16.3856
- PE -14.1086
- Debt/Assets 0.0089
- DivYield 0
- ROE -0.5841
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TRVI | H.C. Wainwright | -- | Buy | -- | $21 | May 28, 2025 |
| Reiterated | TRVI | Needham | -- | Buy | $8 | $25 | March 10, 2025 |
| Upgrade | TRVI | Raymond James | Outperform | Strong Buy | $9 | $29 | March 10, 2025 |
| Reiterated | TRVI | H.C. Wainwright | -- | Buy | $6 | $7.5 | Dec. 12, 2024 |
| Resumed | TRVI | Leerink Partners | -- | Outperform | $6 | $7 | Sept. 9, 2024 |
| Initiation | TRVI | Raymond James | -- | Outperform | -- | $9 | Aug. 30, 2024 |
| Initiation | TRVI | H.C. Wainwright | -- | Buy | -- | $6 | Aug. 30, 2024 |
News
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
Published: June 02, 2025 by: Benzinga
Sentiment: Positive
Trevi Therapeutics, Inc. TRVI revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165).
Read More
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Read More
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Published: June 01, 2025 by: PRNewsWire
Sentiment: Neutral
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn.
Read More
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 195.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
Published: March 10, 2025 by: Benzinga
Sentiment: Positive
On Monday, Trevi Therapeutics, Inc. TRVI reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough (N=66).
Read More
About Trevi Therapeutics, Inc. (TRVI)
- IPO Date 2019-05-07
- Website https://www.trevitherapeutics.com
- Industry Biotechnology
- CEO Jennifer L. Good
- Employees 31